WallStreetZen

NYSE: GSK
Glaxosmithkline Plc Stock

$37.91+0.13 (0.34%)
Updated May 6, 2021
GSK Price
$37.91
Fair Value Price
N/A
Market Cap
$102.08B
52 Week Low
$33.26
52 Week High
$43.18
P/E
13.12x
P/B
5.01x
P/S
2.16x
PEG
3.84x
Dividend Yield
5.51%
Revenue
$44.42B
Earnings
$7.20B
Gross Margin
66.1%
Operating Margin
20.98%
Profit Margin
16.2%
Debt to Equity
3.84
Operating Cash Flow
$13B
Beta
0.61
Next Earnings
N/A
Ex-Dividend
May 20, 2021
Next Dividend
Jul 8, 2021

Zen Score

High
Medium
Low
54
Industry average

Reasons for this score

GSK ($37.91) is trading below its intrinsic value of $89.48, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
GSK is good value based on its earnings relative to its share price (13.12x), compared to the US market average 27.98x)
Valuation
GSK is good value based on its earnings relative to its share price (13.12x), compared to the US Drug Manufacturers - General industry average (32.61x)
Valuation

1 of 13

GSK News

Valuation

GSK price to earnings (PE)

For valuing profitable companies with steady earnings
Company
13.12x
Industry
32.61x
Market
27.98x
GSK is good value based on its earnings relative to its share price (13.12x), compared to the US market average 27.98x)
Valuation
GSK is good value based on its earnings relative to its share price (13.12x), compared to the US Drug Manufacturers - General industry average (32.61x)
Valuation

GSK price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
5.01x
Industry
5.32x
Market
0.6x
GSK is poor value based on its book value relative to its share price (5.01x), compared to the US market average (0.6x)
Valuation
GSK is good value based on its book value relative to its share price (5.01x), compared to the US Drug Manufacturers - General industry average (5.32x)
Valuation

GSK price to earnings growth (PEG)

For valuing profitable companies with growth potential
GSK is poor value relative to its rate of earnings growth, measured by PEG ratio (3.84x)
Valuation

GSK's financial health

Profit margin

Revenue
$10.2B
Net Income
$1.5B
Profit Margin
14.5%
GSK's Earnings (EBIT) of $9.32B can safely cover interest payments on company debt ($35.92B)
Financials
GSK's profit margin has increased (+0.9%) in the last year from (15.3%) to (16.2%)
Financials

Assets to liabilities

Assets
$107.0B
Liabilities
$78.2B
Debt to equity
1.76
GSK's short-term liabilities ($27.77B) exceed its short-term assets ($25.38B)
Financials
GSK's long-term liabilities ($50.40B) exceed its short-term assets ($25.38B)
Financials
GSK's debt relative to shareholder equity (3.84) has decreased or remained constant compared to 5 years ago (17.07)
Financials
GSK's debt to equity ratio (3.84) is considered high
Financials

Cash flow

Operating
$665.8M
Investing
-$65.8M
Financing
-$1.9B
GSK's operating cash flow ($12.82B) is sufficient to service the company's debt ($35.92B)
Financials

Glaxosmithkline Stock FAQ

What is Glaxosmithkline's quote symbol?

(NYSE: GSK) Glaxosmithkline trades on the NYSE under the ticker symbol GSK. Glaxosmithkline stock quotes can also be displayed as NYSE: GSK.

What is the 52 week high and low for Glaxosmithkline (NYSE: GSK)?

(NYSE: GSK) Glaxosmithkline's 52-week high was $43.18, and its 52-week low was $33.26. It is currently -12.2% from its 52-week high and 13.98% from its 52-week low.

How much is Glaxosmithkline stock worth today?

(NYSE: GSK) Glaxosmithkline currently has 5,385,189,617 outstanding shares. With Glaxosmithkline stock trading at $37.91 per share, the total value of Glaxosmithkline stock (market capitalization) is $102.08B.

Glaxosmithkline stock was originally listed at a price of $47.88 in Dec 31, 1997. If you had invested in Glaxosmithkline stock at $47.88, your return over the last 23 years would have been -20.81%, for an annualized return of -1.01%.

How much is Glaxosmithkline's stock price per share?

(NYSE: GSK) Glaxosmithkline stock price per share is $37.91 today (as of May 6, 2021).

What is Glaxosmithkline's Market Cap?

(NYSE: GSK) Glaxosmithkline's market cap is $102.08B, as of May 9, 2021.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Glaxosmithkline's market cap is calculated by multiplying GSK's current stock price of $37.91 by GSK's total outstanding shares of 5,385,189,617.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.